Matthew T. Wolf, Ph.D.
The Wolf lab investigates immunomodulatory biomaterials for cancer immunotherapy, cancer vaccines, and patient-specific tumor models in-a-dish. Dr. Wolf is a biomedical engineer at the forefront of integrating biomaterials science, cancer immunology, and tissue engineering in cancer treatment.
1) biomaterials, 2) cancer immunology, 3) extracellular matrix, 4) 3D culture, 5) tissue engineering, 6) host response to biomaterials
Cancer Biomaterials Engineering
The Cancer Biomaterials Engineering Section is a multidisciplinary combination of biomaterials science, cancer immunology, and tissue engineering. The lab is led by Dr. Matthew Wolf, and investigates immunomodulatory biomaterials for use in next-generation cancer immunotherapies. Biomaterials are made from a diverse range of substances, from plastics to collagen, and are important tools in medicine. Examples include artificial joints, vascular stents, reconstructive surgery after car accidents, or even replacing entire tissues like heart valves. However, biomaterials also have the ability to initiate and regulate inflammation in ways that depend on its physical and chemical composition. We aim to integrate immunomodulatory biomaterials with immune oncology – the study of the immune system’s role in recognizing and fighting cancer. Decoding the cellular and molecular processes at the biomaterial-tissue interface enables us to control immunity for more effective cancer immunotherapy, cancer vaccines, and patient-specific tumor models in-a-dish. Understanding the reverse (how cancer hijacks the immune response to materials), will aid in developing regenerative medicine therapies for cancer patients who have impaired wound healing.
The Lab studies both tissue-derived and synthetic biomaterials as immune regulators during cancer defense in the following project areas: (1) Tumor extracellular matrix scaffolds for 3D organoid tumor modeling. (2) Biomaterial biophysical regulation of tumor antigen presentation. (3) The biomaterial foreign body response in cancer immune surveillance.
View Dr. Wolf's Google Scholar page.
Selected Key Publications
A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy.Sci Transl Med. 11(477): eaat7973, 2019. [ Journal Article ]
- Nat Methods. 12(12): 1197-204, 2015. [ Journal Article ]
- Biomaterials. 35(25): 6838-49, 2014. [ Journal Article ]
Two-Year Follow-Up and Remodeling Kinetics of ChonDux Hydrogel for Full-Thickness Cartilage Defect Repair in the Knee.Epub ahead of print, 2018. [ Journal Article ]
- Biomaterials. 3(10): 2916-25, 2012. [ Journal Article ]
Dr. Matthew Wolf earned his doctoral degree in Bioengineering at the University of Pittsburgh, Swanson School of Engineering under Dr. Stephen F. Badylak where he developed biologic scaffolds for muscle tissue engineering. His postdoctoral training was conducted in Dr. Jennifer Elisseeff’s lab at Johns Hopkins University within the Translational Tissue Engineering Center (TTEC) and the Bloomberg~Kimmel Institute for Cancer Immunotherapy where he studied the immunological determinants of biomaterial-tumor interactions. During this time, he was awarded the Hartwell Foundation Postdoctoral Fellowship (2016) and was recipient of the Regenerative Medicine Workshop Young Investigator Postdoctoral Award (2019). He was appointed as a Research Associate in Johns Hopkins Biomedical Engineering in 2019. Dr. Wolf joined the National Cancer Institute as an Earl Stadtman Tenure-Track Investigator in August, 2020 where he studies immunomodulatory biomaterials to augment cancer immunotherapy.
|Elizabeth Brooks Ph.D.||Postdoctoral Fellow (CRTA)|
|Michael Buckenmeyer Ph.D.||Postdoctoral Fellow (CRTA)|